GlassScriptPhysician profile
Mark F Tsai
NPI 1962566950
$6,984.16
in general payments reported to CMS, 2019-2025
24 companies · $20.43 in 2025
The $20.43 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,131 · 2020: $767 · 2021: $764 · 2022: $302 · 2025: $20.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,397.27 | 2019-2021 | |
| Abbvie INC. | $1,288.63 | 2019-2022 | |
| Amarin Pharma, INC. | $606.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $499.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $442.23 | 2019 | |
| Allergan, INC. | $383.26 | 2019-2020 | |
| Gilead Sciences, INC. | $278.90 | 2019-2025 | |
| Pfizer INC. | $249.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.12 | 2019 | |
| Intercept Pharmaceuticals, INC. | $141.42 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $119.31 | 2021 | |
| Merck Sharp & Dohme LLC | $118.00 | 2019 | |
| Glaxosmithkline, LLC. | $117.27 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $92.41 | 2019 | |
| Braintree Laboratories, INC. | $79.24 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $62.28 | 2022 | |
| Nestle Healthcare Nutrition INC. | $62.23 | 2021-2022 | |
| Janssen Biotech, INC. | $60.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.47 | 2019 | |
| Daiichi Sankyo INC. | $45.54 | 2019-2020 | |
| Celgene Corporation | $22.23 | 2022 | |
| Shionogi INC | $16.58 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.